Monmouth Junction-based Ayala Pharmaceuticals, Inc. is making significant strides in the field of oncology, focusing on the development and commercialization of small molecule therapeutics for people with rare tumors and aggressive cancers. In addition, Ayala Pharmaceuticals is utilizing its proprietary Lm-based antigen delivery products to benefit patients with common cancers. The company is developing two lead candidates, AL102 and ADXS-504, with the former targeting the aberrant activation of the Notch pathway using gamma secretase inhibitors and the latter being an Lm-based therapy for early-stage prostate cancer. Founded in 2017, Ayala Pharmaceuticals is a clinical-stage oncology company with a promising vision for treating cancer patients.